USP7 and neoplasm: Additionally, transfection of HCT8 cells with specific shRNAs targeting USP7 (Fig. 5C–E) or treatment of RKO cells with the USP7 inhibitor P5091 (Fig. 5F–H) significantly inhibited tumor volume growth and weight, which was largely reversed in the context of DACH1 overexpression.